A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents

Bibliography

• Ng M, Fleming T, Robinson M, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014;384:766-81
   PubMed Web of Science ®Google Scholar
• Obesity and overweight. WHO media centre. Available from: http://www.who.int/mediacentre/factsheets/fs311/en/index.html [Last accessed 28 November 2014]
   Google Scholar
• Zhang Z, Wang M. Obesity, a health burden of a global nature. Acta Pharmacol Sinica 2012;33:145-7
   PubMed Web of Science ®Google Scholar
• Rodgers RJ, Tschop MH, Wilding JP. Anti-obesity drugs: past, present and future. Dis Model Mech 2012;5:621-6
   PubMed Web of Science ®Google Scholar
• Powell AG, Apovian CM, Aronne LJ. New drug targets for the treatment of obesity. Clin Pharmacol Ther 2011;90:40-51
   PubMed Web of Science ®Google Scholar
• Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm312468.html [Last accessed 28 November 2014]
   Google Scholar
• FDA Approves Contrave (bupropion/naltrexone) for Weight Management. Available from: http://www.drugs.com/newdrugs/fda-approves-contrave-bupropion-naltrexone-weight-management-4081.html [Last accessed 12 June 2015]
   Google Scholar
• Bivalent pyrazole derivatives as food intake inhibitors. WO2010/128191A1; 2010
   Google Scholar
• Kennett GA, Clifton PG. New approaches to the pharmacological treatment of obesity: Can they break through the efficacy barrier? Parmacol Biochem Behav 2010;97:63-83
   PubMed Web of Science ®Google Scholar
• Storr MA, Bashashati M, Hirota C, et al. Differential effects of CB1 neutral antagonists and inverse agonists on gastrointestinal motility in mice. Neurogastroennterol motil 2010;22:787-e223
   PubMedGoogle Scholar
• Di Marzo V. Endocannabinoids: synthesis and degradation. Rev Physiol biochem Pharmacol 2006;160:1-24
   Web of Science ®Google Scholar
• Perkins JM, Davis SN. Endocannabinoid system overactivity and the metabolic syndrome: prospects for treatment. Curr Diab Rep 2008;8:12-19
   PubMed Web of Science ®Google Scholar
• Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005;353:2121-34
   PubMed Web of Science ®Google Scholar
• Ducobu J, Sternon J. Rimonabant (Acomplia), specific inhibitor of the endocannabinoid system. Rev Med Brux 2005;26:165-8
   PubMedGoogle Scholar
• Gelfand EV, Cannon CP. Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors. J Am coll cardiol 2006;47:1919-26
   PubMed Web of Science ®Google Scholar
• Nisoli E. Endocannabinoids and obesity development – the adipose tissue. Drug Discov Today Dis Mech 2010;7:e199-04
   Google Scholar
• de Kloet AD, Woods SC. Minireview: Endocannabinoids and Their Receptors as Targets for Obesity Therapy. Endocrinology 2009;150:2531-6
   PubMed Web of Science ®Google Scholar
• Matsuda LA, Lolait SJ, Brownstein MJ, et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990;346:561-4
   PubMed Web of Science ®Google Scholar
• Breivogel CS, Griffin G, Di Marzo V, et al. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol 2001;60:155-63
   PubMed Web of Science ®Google Scholar
• Begg M, Pacher P, Batkai S, et al. Evidence for novel cannabinoid receptors. Pharmacol Therap 2005;106:133-45
   PubMed Web of Science ®Google Scholar
• Pertwee RG, Howlett AC, Abood ME, et al. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid Receptors and Their Ligands: Beyond CB1 and CB2. Pharmacol Rev 2010;62:588-31
   PubMed Web of Science ®Google Scholar
• Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993;365:61-5
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay S, Shim JY, Assi AA, et al. CB(1) cannabinoid receptor-G protein association: a possible mechanism for differential signaling. Chem Phys lipids 2002;121:91-109
   PubMed Web of Science ®Google Scholar
• Bisogno T, Ligresti A, Di Marzo V. The endocannabinoid signalling system: biochemical aspects. Pharmacol Biochem Behav 2005;81:224-38
   PubMed Web of Science ®Google Scholar
• Bosier B, Muccioli GG, Hermans E, Lambert DM. Functionally selective cannabinoid receptor signalling: therapeutic implications and opportunities. Biochem Pharmacol 2010;80:1-12
   PubMed Web of Science ®Google Scholar
• Turu G, Hunyady L. Signal transduction of the CB1 cannabinoid receptor. J Mol Endocrinol 2010;44:75-85
   PubMed Web of Science ®Google Scholar
• Muccioli GG, Lambert DM. Current knowledge on the antagonists and inverse agonists of cannabinoid receptors. Curr Med Chem 2005;12:1361-94
   PubMed Web of Science ®Google Scholar
• Sink KS, McLaughlin PJ, Wood JA, et al. The novel cannabinoid CB1 receptor neutral antagonist AM4113 suppresses food intake and food-reinforced behavior but does not induce signs of nausea in rats. Neuropsychopharmacology 2008;33:946-55
   PubMed Web of Science ®Google Scholar
• Pavon FJ, Bilbao A, Hernandez-Folgado L, et al. Antiobesity effects of the novel in vivo neutral cannabinoid receptor antagonist 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-1,2,4-triazole-LH 21. Neuropharmacology 2006;51:358-66
   PubMed Web of Science ®Google Scholar
• Kirilly E, Gonda X, Bagdy G. CB1 receptor antagonists: new discoveries leading to new perspectives. Acta Physiol 2012;205:41-60
   Google Scholar
• Price MR, Baillie GL, Thomas A, et al. Allosteric modulation of the cannabinoid CB1 receptor. Mol Pharmacol 2005;68:1484-95
   PubMed Web of Science ®Google Scholar
• Horswill JG, Bali U, Shaaban S, et al. PSNCBAM-1, a novel allosteric antagonist at cannabinoid CB1 receptors with hypophagic effects in rats. Br J Pharmacol 2007;152:805-14
   PubMed Web of Science ®Google Scholar
• Cota D, Marsicano G, Tschop M, et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003;112:423-31
   PubMed Web of Science ®Google Scholar
• Di Marzo V, Matias I. Endocannabinoid control of food intake and energy balance. Nat Neurosci 2005;8:585-9
   PubMed Web of Science ®Google Scholar
• Engeli S, Bohnke J, Feldpausch M, et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes 2005;54:2838-43
   PubMed Web of Science ®Google Scholar
• Vettor R, Pagano C. The role of the endocannabinoid system in lipogenesis and fatty acid metabolism. Best Pract Res Clin Endocrinol Metab 2009;23:51-63
   PubMed Web of Science ®Google Scholar
• Sharma MK, Murumkar PR, Kanhed AM, et al. Prospective therapeutic agents for obesity: Molecular modification approaches of centrally and peripherally acting selective cannabinoid 1 receptor antagonists. Eur J Med Chem 2014;79:298-39
   PubMed Web of Science ®Google Scholar
• Bermudez-Silva FJ, Viveros MP, McPartland JM, et al. The endocannabinoid system, eating behavior and energy homeostasis: the end or a new beginning? Pharmacol Biochem Behav 2010;95:375-82
   PubMed Web of Science ®Google Scholar
• Goya P, Jagerovic N. Recent advances in cannabinoid receptor agonists and antagonists. Expert Opin Ther Pat 2000;10:1529-38
   Web of Science ®Google Scholar
• Adam J, Cowley P. Recent advances in the cannabinoids. Expert Opin Ther Pat 2002;12:1475-89
   Web of Science ®Google Scholar
• Hertzog DL. Recent advances in the cannabinoids. Expert Opin Ther Pat 2004;14:1435-52
   Web of Science ®Google Scholar
• Muccioli GG, Lambert DM. Latest advances in cannabinoid receptor antagonists and inverse agonists. Expert Opin Ther Pat 2006;16:1405-23
   Web of Science ®Google Scholar
• Lambert DM. CB1 cannabinoid receptor antagonism for treating inflammation and arthritis. Expert Opin Ther Pat 2007;17:1027-31
   Web of Science ®Google Scholar
• Sanofi-Aventis. Thiophene-2-carboxamide derivatives and use thereof as cannabinoid CB-1 receptor antagonists. WO2005/035488A3; 2005
   Google Scholar
• Sanofi-Aventis. Thiophene-2-carboxamide, derivatives thereof and therapeutic use thereof. US2011/0183960A1; 2011
   Google Scholar
• Sanofi-Aventis. Pyrrole derivatives, preparation of same and therapeutic application thereof. WO2009/141533A2; 2009
   Google Scholar
• Sanofi-Aventis. Pyrrole derivatives, preparation of same and therapeutic application thereof. US2011/0144157A1; 2011
   Google Scholar
• Sanofi. Pyrrole derivatives, preparation of same and therapeutic application thereof. US8383666B2; 2013
   Google Scholar
• Sanofi-Aventis. Pyrrole derivatives, preparation of same and therapeutic application thereof. WO2009/141532A2; 2009
   Google Scholar
• Sanofi. Pyrrole derivatives, their preparation and their therapeutic application. US2014/8680102B2; 2014
   Google Scholar
• Sanofi-Aventis. Pyrrole derivatives, their preparation and their therapeutic application. US2011/0152320A1; 2011
   Google Scholar
• Solvay Pharmaceuticals B.V. Sulphur containing pyrazole derivatives as selective cannabinoid CB1 receptor antagonists. WO2007/138050A1; 2007
   Google Scholar
• Solvay Pharmaceuticals B.V. Sulphur containing pyrazole derivatives as selective cannabinoid CB1 receptor antagonists. US 7786144B2; 2010
   Google Scholar
• Solvay Pharmaceuticals B.V. Sulphur containing pyrazole derivatives as selective cannabinoid CB1 receptor antagonists. US8461184B2; 2013
   Google Scholar
• Tanabe Seiyaku Co. Ltd. Pyrazole compounds having cannabinoid receptor (CB1) antagonizing activity. WO2007/046550; 2007
   Google Scholar
• Mitsubishi Tanabe Pharma Corp. Pyrazole compounds having cannabinoid receptor (CB1) antagonizing activity. US7872006B2; 2011
   Google Scholar
• Astrazeneca UK Ltd. Pyrazole derivatives as therapeutic agents. WO2007/020388A1; 2007
   Google Scholar
• Research Triangle Institute. Compounds having unique CB1 receptor binding selectivity and methods for their production and use. EP1494673B1; 2008
   Google Scholar
• 7TM Pharma A/S Pyrazole derivatives as modulators of cannabinoid receptor. WO2008/074982A1; 2008
   Google Scholar
• 7TM Pharma A/S CB1 receptor modulators. US8124634B2; 2012
   Google Scholar
• National Health Research Institutes. Thiophene compounds. US2008/0090810A1; 2008
   Google Scholar
• National Health Research Institutes. Oxadiazole compounds. US77055024B2; 2010
   Google Scholar
• Green Cross Corp. Heteroaryl pyrazole derivatives as cannabinoid CB1 receptor antagonists. WO2008/039023A1; 2008
   Google Scholar
• Green Cross Corp. Heteroaryl- pyrazole derivatives as cannabinoid CB1 receptor antagonists. US7875647B2; 2011
   Google Scholar
• Green Cross Corp. Heteroaryl- pyrazole derivatives as cannabinoid CB1 receptor antagonists. US2008/0081812A1; 2008
   Google Scholar
• Green Cross Corp. Biarylpyrazole-4-carboxamides as cannabinoid CB1 receptor ligands. WO2009/078498A1; 2009
   Google Scholar
• Green Cross Corp. Sulfur containing pyrazole-heterocycle derivatives as cannabinoid CB1 receptor antagonists. WO2010/035915A; 2010
   Google Scholar
• Green Cross Corp. Sulfur containing pyrazole-heterocycle derivatives as cannabinoid CB1 receptor antagonists. US8309584B2; 2012
   Google Scholar
• 7TM Pharma A/S. Cannabinoid receptor modulators. WO2008/059207A1; 2008
   Google Scholar
• 7TM Pharma A/S. Cannabinoid receptor modulators. US2012/8173680B2; 2012
   Google Scholar
• 7TM Pharma A/S. Cannabinoid receptor modulators. US2010/0292273A1; 2010
   Google Scholar
• Jenrin Discovery. Cannabinoid receptor antagonists/inverse agonists useful for treating obesity. WO2009/033125A1; 2009
   Google Scholar
• Janssen Pharmaceutica. Substituted 5-vinylphenyl-1-phenyl-pyrazole cannabinoid modulators. US 2011/0178148A1; 2011
   Google Scholar
• The University Court of the University of Aberdeen. 1,5-Diaryl-pyrazoles as cannabinoid receptor neutral antagonists useful as therapeutic agents. US2010/0022611A1; 2010
   Google Scholar
• University of Connecticut. The novel hetero pyrrole analogs acting on cannabinoid receptors. WO2010/104488A1; 2010
   Google Scholar
• University of Connecticut. Heteropyrrole analogs acting on cannabinoid receptors. US8410097B2; 2013
   Google Scholar
• University of Connecticut. CB1 receptor antagonists and uses thereof. WO2008/154015A1; 2008
   Google Scholar
• University of Connecticut. CB1 receptor antagonists and uses thereof. US2012/8293211B2; 2012
   Google Scholar
• University of Connecticut. CB1 receptor antagonists and uses thereof. US2013/0123229A1; 2013
   Google Scholar
• Sanofi-Aventis. Derivatives of N-[(1,5-diphenyl-1H-Pyrazol-3-yl)methyl sulfonamide, their preparation and their application in therapeutics. US7875646B2; 2011
   Google Scholar
• Research Triangle Institute. Pyrazole derivatives as cannabinoid receptor 1 antagonists. WO2012/174362A1; 2012
   Google Scholar
• Research Triangle Institute. Pyrazole derivatives as cannabinoid receptor 1 antagonists. US2014/0107157A1; 2014
   Google Scholar
• Solvay Pharmaceuticals. Tetrasubstituted imidazole derivatives as cannabinoid CB1 receptor modulators with a high CB1/CB2 receptor subtype selectivity. EP1756066; 2008
   Google Scholar
• Green Cross Corp. Heteroaryl imidazole derivatives as cannabinoid CB1 receptor antagonists. WO2008/105607A1; 2008
   Google Scholar
• University of Connecticut. Heteropyrrole analogs acting on cannabinoid receptors. US8410097B2; 2013
   Google Scholar
• National Tsing Hua University. 1,2,3-Triazole derivatives as new cannabinoid-1 receptor antagonists. US2010/0144734A1; 2010
   Google Scholar
• Solvay Pharmaceuticals B.V. 1H-1,2,4-triazole-3-carboxamide derivatives as cannabinoid-CB sb 1/sb receptor ligands. EP1542678B1; 2010
   Google Scholar
• Solvay Pharmaceuticals B.V. 1,3,5-trisubstituted 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity. EP1713475B1; 2008
   Google Scholar
• Solvay Pharmaceuticals B.V. Synthesis of 3,4-diaryl-4,5-dihydro-(1H)-pyrazole-1-carboxamide derivatives. WO2010/012797A2; 2010
   Google Scholar
• Solvay Pharmaceuticals B.V. (5R)-1,5-diaryl-4,5-dihydro-1H-pyrazole-3-carboxamidine derivatives having CBl-antagonistic activity. US2011/0053983A1; 2011
   Google Scholar
• Jenrin Discovery. Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes. US2007/0259934A1; 2007
   Google Scholar
• Jenrin Discovery. Substituted N-phenyl-5-phenyl-pyrazolin-3-yl amides as cannabinoid receptor antagonists/inverse agonists useful for treating obesity. US 2009/0286758A1; 2009
   Google Scholar
• Jenrin Discovery. Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes. WO2009/059264A1; 2009
   Google Scholar
• Jenrin Discovery. Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes. US2010/0105751A1; 2010
   Google Scholar
• Jenrin Discovery. Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes. WO2012/068529A2; 2012
   Google Scholar
• Jenrin Discovery. Cannabinoid receptor antagonists/inverse agonists. WO2014/018695A1; 2014
   Google Scholar
• Jenrin Discovery. Cannabinoid receptor antagonists/inverse agonists useful for treating disease conditions, including metabolic disorders and cancers. US8680131B2; 2014
   Google Scholar
• Jenrin Discovery. Cannabinoid receptor antagonists/inverse agonists useful for treating disease conditions, including metabolic disorders and cancers. US2014/0031404A1; 2014
   Google Scholar
• Laboratorios Del Dr. Esteve, S.A. 4-Methyl-4,5-dihydro-1H-pyrazole-3-carboxamide useful as a cannabinoid CB1 neutral antagonist. WO2009/124950A2; 2009
   Google Scholar
• Laboratorios Del Dr. Esteve, S.A. 4-Methyl-4,5-dihydro-1H-pyrazole-3-carboxamide useful as a cannabinoid CB1 neutral antagonist. US2011/0028517A1; 2011
   Google Scholar
• Solvay Pharmaceuticals, B.V. Imidazoline derivatives having CB1-antagonistic activity. US7495108B2; 2009
   Google Scholar
• Solvay Pharmaceuticals, B.V. Imidazoline derivatives having CB1-antagonistic activity. EP 2008/1725536B1; 2008
   Google Scholar
• Eli Lilly & CO. 1,5-Diphenyl-pyrrolidin-2-one compounds as CBl ligands. WO2009/131815A1; 2009
   Google Scholar
• Eli Lilly & CO. 1,5-Diphenyl-pyrrolidin-2-one compounds as CBl ligands. US2011/0034484A1; 2011
   Google Scholar
• Eli Lilly & CO. 1,5-Diphenyl-pyrrolidin-2-one compounds as CB-l ligands. US8420654B2; 2013
   Google Scholar
• Eli Lilly & CO. CB1 compounds. WO2008/070305A2; 2008
   Google Scholar
• Eli Lilly & CO. 1,5-Diphenyl-3-benzylamino-1,5-dihydropyrolidin-2-one as CB1 receptor modulators. US8168659B2; 2012
   Google Scholar
• Merck Sharp & Dohme Corp. Substituted furo[2,3-b]pyridine derivatives as cannabinoid-1 receptor modulators. EP2146997B1; 2010
   Google Scholar
• Merck & Co., Inc. Substituted pyrano[2,3-b]pyridine derivatives as cannabinoid-1-receptor modulatos. WO2008/094476A1; 2008
   Google Scholar
• Merck & Co., Inc. Substituted pyrano[2,3-b]pyridine derivatives as cannabinoid-1-receptor modulatos. EP2109615B1; 2011
   Google Scholar
• Schering Corp. Diaryl morpholines as CB1 modulators. WO2008/130616 A2; 2008
   Google Scholar
• Schering Corp. Diaryl morpholines as CB1 modulators. US2010/0197564A1; 2010
   Google Scholar
• Schering Corp. Substituted piperazines as CB1 antagonists. WO2009/005645A1; 2009
   Google Scholar
• Intervet Inc. Substituted piperazines as CB1 antagonists. WO2009/005646A3; 2009
   Google Scholar
• Intervet Inc. Substituted piperazines as CB1 antagonists. US8623873B2; 2014
   Google Scholar
• Tanabe Seiyaku Co., Ltd. Pyrazolo[1,5-a]pyrimidine compounds as cannabinoid receptor antagonists. WO2007/046548A1; 2007
   Google Scholar
• Mitsubishi Tanabe Pharma Corp. Pyrazolo[1,5-a]pyrimidine compounds. US8188097B2; 2012
   Google Scholar
• Mitsubishi Tanabe Pharma Corp. Pyrazolo[1,5-a]pyrimidine compounds as CB1 receptor antagonists. EP2520577A1; 2012
   Google Scholar
• Mitsubishi Tanabe Pharma Corp. A pyrazolo[1,5-a]pyrimide compound. WO2008/004698A3; 2008
   Google Scholar
• Mitsubishi Tanabe Pharma Corp. Pyrazolo[1,5-a]pyrimidine compounds as CB1 receptor antagonist. US2009/0258867A1; 2009
   Google Scholar
• Mitsubishi Tanabe Pharma Corp. Pyrazolo[1,5-a]pyrimidine compounds as CB1 receptor antagonist. EP2035427; 2013
   Google Scholar
• Merck and Co., Inc. Substituted pyrido[2,3-d]pyrimidine derivatives as cannabinoid-l receptor modulators. US2010/0063032A1; 2010
   Google Scholar
• Merck and Co., Inc. Substituted pyrido[3,2-E][1,2,4]triazole[4,3-c]pyrimidine derivatives as cannabinoid-l receptor modulators. US2010/0029697A1; 2010
   Google Scholar
• Jenrin Discovery Inc. Purine compounds as cannabinoid receptor blockers. US2012/8252791B2; 2012
   Google Scholar
• Jenrin Discovery. Purine compounds as cannabinoid receptor blockers. US2010/0041650A1; 2010
   Google Scholar
• Research Triangle Institute. Peripherally restricted diphenyl purine derivatives. WO2013/123335A1; 2013
   Google Scholar
• Janssen Pharmaceutica NV. Tetrahydro-lH-1,2,6-triaza-azulene cannabinoid modulators. US8012957B2; 2011
   Google Scholar
• Laboratorios Del Dr. Esteve. Substituted azetidine compounds, their preparation and use as medicaments. US2007/0066587A1; 2007
   Google Scholar
• Merck & Co., Inc. Heterocyclic-substituted 3-alkyl azetidine derivatives. WO2007/062193A1; 2007
   Google Scholar
• Merck & Co., Inc. Heterocyclic-substituted 3-alkyl azetidine derivatives. US2007/0293505A1; 2007
   Google Scholar
• Vernalis Research Ltd. Azetidinecarboxamide derivatives and their use in the treatment of CB1 receptor mediated disorders. EP1620395B1; 2009
   Google Scholar
• Jenrin Discovery. Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes. US2011/0160179A1; 2011
   Google Scholar
• Jenrin Discovery. Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes. US2009/01917857A1; 2009
   Google Scholar
• Sanofi-Aventis. Azetidine-derived compounds, preparation method therefore and therapeutic use of same. US2011/0053908A1; 2011
   Google Scholar
• Sanofi-Aventis. Substituted imidazoline-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof. US2011/112097A1; 2011
   Google Scholar
• Amorepacific Corp. Novel compound acting as a cannabinoid receptor-1 inhibitor. WO2012/030170A3; 2012
   Google Scholar
• Amorepacific Corp. Novel compound acting as a cannabinoid receptor-1 inhibitor. US2013/0158025; 2013
   Google Scholar
• Astrazeneca AB. Benzimidazole derivatives which are to be used as antagonists for the CB1-receptor. WO2007/145563A1; 2007
   Google Scholar
• Merck and Co., Inc. Sulfonylated piperazines as cannabinoid-l receptor modulators. US2009/0247499A1; 2009
   Google Scholar
• The University Court of the University of Aberdeen. N-(arylalkyl)-1H-indole-2-sulfonic acid amide compounds and their therapeutic use as cannabinoid allosteric modulators. WO2012/117216A1; 2012
   Google Scholar
• The Board of Trustees of the university of Arkansas. Use of the aminoalkylindole JWH-073-M4 and related compounds as neutral CB1 receptor antagonists for the treatment of alcoholism, drug abuse, obesity, obesity, and obesity-related diseases. WO2013/106349A1; 2013
   Google Scholar
• INSERM. Antagonists of CB1 receptor. WO2012/160006A1; 2012
   Google Scholar
• Chorvat RJ, Berbaum J, Seriacki K, McElroy JF. JD-5006 and JD-5037: Peripherally restricted (PR) cannabinoid-1 receptor blockers related to SLV-319 (Ibipinabant) as metabolic disorder therapeutics devoid of CNS liabilities. Bioorg Med Chem Lett 2012;22:6173-80
   PubMed Web of Science ®Google Scholar
• Pipeline. Jenrin Discovery. Available from: http://www.jenrindiscovery.com/pipeline.html [Last accessed 04 February 2015]
   Google Scholar
• Tam J, Vemuri VK, Liu J, et al. Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J Clin Invest 2010;120:2953-66
   PubMed Web of Science ®Google Scholar
• Drug Pipeline. MAKScientific. Available from: http://makscientific.com/drug_pipeline.html [Last accessed 04 February 2015]
   Google Scholar
• 7TM Pharma Successfully Conducts Clinical Phase I Trial of Its First in Class Peripheral CB1 Receptor Antagonist TM38837 Demonstrating Restriction from the Human CNS. Biospace. Available from: http://www.biospace.com/News/7tm-pharma-successfully-conducts-clinical-phase-i/202230 [Last accessed 04 February 2015]
   Google Scholar
• Hung MS, Chang CP, Li TC, et al. Discovery of 1-(2,4-dichlorophenyl)-4-ethyl-5-(5-(2-(4-(trifluoromethyl)phenyl)ethynyl)thiophen-2-yl)-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide as a potential peripheral cannabinoid-1 receptor inverse agonist. Chem Med Chem 2010;5:1439-43
   Web of Science ®Google Scholar
• Klumpers LE, Fridberg M, de Kam ML, et al. Peripheral selectivity of the novel cannabinoid receptor antagonist TM38837 in healthy subjects. Br J Clin Pharmacol 2013;76:846-57
   PubMed Web of Science ®Google Scholar
• Sharma MK, Murumkar PR, Giridhar R, Yadav MR. Exploring structural requirements for peripherally acting 1,5-diaryl pyrazole containing cannabinoid 1 receptor antagonists for the treatment of obesity. Mol Divers 2015. doi: 10.1007/s11030-015-9611-5 In press
   Google Scholar